Spontaneous pneumothorax during nintedanib therapy in patients with systemic sclerosis‐associated interstitial lung disease

Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc). Nintedanib, an antifibrotic drug, has recently been approved for treating SSc‐ILD. Although there have been no reports suggesting the development of pneumothorax with nintedanib use, its safety in patients with imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Sumi, Toshiyuki, Uehara, Hirofumi, Tada, Makoto, Keira, Yoshiko, Kamada, Koki, Shijubou, Naoki, Yamada, Yuichi, Nakata, Hisashi, Mori, Yuji, Chiba, Hirofumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840496/
https://www.ncbi.nlm.nih.gov/pubmed/33552523
http://dx.doi.org/10.1002/rcr2.716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840496/
https://www.ncbi.nlm.nih.gov/pubmed/33552523
http://dx.doi.org/10.1002/rcr2.716

Ejemplares similares